Edition:
United States

Profile: Iovance Biotherapeutics Inc (IOVA.A)

IOVA.A on American Stock Exchange

17.20USD
3:59pm EDT
Change (% chg)

$-0.25 (-1.43%)
Prev Close
$17.45
Open
$17.70
Day's High
$17.70
Day's Low
$17.09
Volume
2,135
Avg. Vol
1,786
52-wk High
$17.95
52-wk Low
$7.27

Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., incorporated on September 17, 2007, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, the Company had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. The Company is collaborating with the National Cancer Institute (NCI) to evaluate unmodified TIL in other solid tumor indications, such as ocular (uveal) melanoma, bladder, breast and lung cancer. The Company is also collaborating with Karolinska University Hospital to conduct clinical trials of TIL manufactured using a cytokine cocktail for expansion in pancreatic cancer and glioblastoma.

The Company is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda (pembrolizumab). The Company's manufacturing and processing of TIL-based product candidates is based on the NCI's original manufacturing and processing of TIL. The processing of LN-144 begins with the collection of the patient's tumor, which is then sent to a central processing facility, where the T cells are isolated. These cells are stimulated to proliferate, then propagated in cell culture flasks until sufficient cells are available for infusion back into the patient. The TIL is then washed and put in media suitable for infusion at the cell processing site and shipped back to the clinical center where they can be administered to the patient. In preparation for administration of the TIL, the patient undergoes a short chemotherapy lymphodepletion regimen, which is intended to improve the survival and proliferative capacity of the newly infused T-cells.

The Company competes with Amgen, AstraZeneca, Bristol-Myers, Merck and Roche.

Company Address

Iovance Biotherapeutics Inc

999 Skyway Rd Ste 150
SAN CARLOS   CA   94070-2724
P: +1650.2607120
F: +1302.7301370

Company Web Links